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Abstract Dengue, classified as a ‘neglected topical disease’, is currently regarded
globally as the most important mosquito-borne viral disease, which inflicts sub-
stantial socioeconomic and health burden in many tropical and subtropical regions
of the world. While efforts continue towards developing and improving the efficacy
of a tetravalent vaccine to protect individuals against all dengue virus serotypes,
the long-term epidemiological impact of vaccination remains elusive. We develop
a serotype-specific, vector-host compartmental model to evaluate the effect of vac-
cination in the presence of antibody-dependent enhancement and cross-protection
following recovery from primary infection. Reproducing the reported multi-annual
patterns of dengue infection, our model projects that vaccination can dramatically
reduce the overall incidence of the disease. However, if the duration of vaccine-
induced protection is shorter than the average lifetime of the human population,
vaccination can potentially increase the incidence of severe infection of dengue
hemorrhagic fever due to the effects of antibody-dependent enhancement. The
magnitude and timelines for this increase depend strongly on the efficacy and du-
ration of the vaccine-induced protection. Corresponding to the current estimates
of vaccine efficacy, we show that dengue eradication is infeasible using an imperfect
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vaccine. Furthermore, for a vaccine that induces lifetime protection, a nearly full
coverage of infant vaccination is required for dengue elimination. Our findings sug-
gest that other vector control measures may still play a significant role in dengue
prevention even when a vaccine with high protection efficacy becomes available.
Keywords Dengue fever · Antibody-dependent enhancement · Epidemic
modelling · Vaccination · Simulation
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1 Introduction
Dengue remains a major public health concern globally, especially in tropics across
the world (Gubler and Clark, 1995; Otero et al., 2008; WHO, 2014). Worldwide,
there is an estimated 2.5–3.6 billion individuals who are at risk of dengue infection,
with annual estimates of 50–230 million new cases, 500,000 hospitalizations, and
25,000 fatal outcomes (Wilder-Smith et al, 2012; WHO, 2014). Intervention mea-
sures to manage dengue spread and its impact are mainly based on vector control
programs (Otero et al., 2008; Wallace et al., 2013; Wilder-Smith et al, 2012).
Dengue is caused by four antigenically distinct virus serotypes, designated as
DENv1, DENv2, DENv3 and DENv4 (Carrington and Simmons, 2014; Guzman
and Kouri, 2002). These serotypes can be transmitted from infectious individuals
to susceptible individuals through the bites of infectious mosquitoes, mainly the
Aedes Aegypti mosquitoes. A second type of mosquito, A. Albopictus, is also a
vector for this disease that is becoming increasingly important (Carrington and
Simmons, 2014; Wilder-Smith et al, 2012). In infected humans, disease symptoms
can range from very mild to severe (Gubler and Clark, 1995). The mild form
(called non-haemorrhagic) can cause fever and headache without the usual respi-
ratory symptoms (Carrington and Simmons, 2014). The more severe forms include
dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS), both of which
can be life-threatening, and may be related to a secondary infection caused by a
dengue serotype that is different from the serotype responsible for the primary
infection (Carrington and Simmons, 2014). The risk of severe forms of dengue
infection is associated with the mechanisms of antibody-dependent enhancement
(ADE), by which pre-existing non-neutralizing antibodies form immune complexes
with the new serotype-infecting virus that in turn enhance the capacity to infect
macrophages and other Fcgamma receptor (FcgammaR)-bearing cells (Cummings
et al., 2005; Ferguson et al, 1999a). This phenomenon, although not clinically
proven in efforts towards the development of a dengue vaccine, can have impor-
tant implications for disease outcomes, since the vaccine-induced immunity against
a particular serotype may prime an individual to experience a severe form of DHF
or DSS upon exposure to a different dengue serotype.
Previous modelling studies have investigated the effect of ADE (as a result of
pre-existing cross-protective immunity) in dengue spread, and provided important
insights into the epidemiological patterns of dengue infection observed in various
databases (Coudeville and Garnett, 2012; Cummings et al., 2005; Pandey and
Medlock, 2014; Recker et al., 2014; Reich et al., 2013; Wearing and Rohani, 2006).
While infection with a particular serotype of dengue provides lifetime protection
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against reinfection with that serotype (Carrington and Simmons, 2014), new in-
fections with other serotypes can occur. However, interactions between dengue
serotypes have been shown to confer substantial short-term cross-protection, vir-
tually eliminating the risk of a new infection for a period of 1–4 years after recov-
ery from one serotype of dengue infection (Reich et al., 2013). Once this period
has elapsed, ADE may place the individuals at risk of developing DHF or DSS
depending on the concentration of non-neutralizing antibodies at the time of a
secondary heterologous infection (Cummings et al., 2005; Recker et al., 2014; Re-
ich et al., 2013; Wearing and Rohani, 2006). The ADE effect can therefore increase
the transmissibility of secondary infections to mosquitoes due to high viral titres
(Cummings et al., 2005; Recker et al., 2014; Reich et al., 2013; Wearing and Ro-
hani, 2006). The duration of this increased transmissibility is unknown; however,
it depends on the decay rate of pre-existing non-neutralizing antibodies. The un-
known duration of ADE and its epidemiological impact on transmission dynam-
ics of dengue serotypes remain elusive in understanding the effect of vaccination
against dengue serotypes (Guzman et al., 2010). While vaccination is expected to
reduce the overall incidence of infection (Coudeville and Garnett, 2012; Pandey
and Medlock, 2014), the effect of vaccine-induced ADE remains both clinically and
epidemiologically unaddressed (Guzman et al., 2010).
In this study, we develop a full model of vector-host interactions for the trans-
mission dynamics of dengue to evaluate the potential impact of vaccination and
the vaccine-induced ADE on disease prevention. Key parameters in this evalua-
tion include the serotype-specific vaccine-induced protection, duration of ADE,
increased transmissibility of secondary infection, and reduction of susceptibility to
infection as a result of pre-existing partial protection. We simulate the model with
parameters estimated in previous literature, present the results, and place them
in the context of dengue epidemiology and prevention.
2 Model description
2.1 General assumptions
Since dengue serotypes are reported to be pairwise similar in their transmission
characteristics (Carrington and Simmons, 2014), we considered only two serotypes,
referred to as S1 and S2. Tertiary infections are reported very rarely (Halstead,
2003), and therefore most studies assume that individuals are immune to all four
serotypes of dengue after two heterologous infections. In line with previous work,
we disregard heterologous superinfection. Serotypes S1 and S2 considered here do
not necessarily correspond to the actual DENv1 and DENv2, but rather repre-
sent co-circulation of two serotypes that have different transmissibility. Our model
incorporates S1 and S2 with different rates for human-to-mosquito and mosquito-
to-human transmission (Carrington and Simmons, 2014). While the incubation pe-
riod and the infectious period of dengue in humans may vary for different serotypes
(Carrington and Simmons, 2014), we follow previous work and assume that these
periods are the same for dengue caused by S1 and S2. The schematic diagram of
the model is presented in Figure 1.
Like many multi-strain pathogens, dengue has been studied for evidence of im-
mune response and cross-protection after infection with one serotype. Most studies
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Fig. 1 Schematic model diagram for dengue spread between humans through mosquitoes.
concur that infection with any of the four serotypes induces lifetime immunity to
that serotype, and confers at least short-term cross-protection against all other
serotypes. Several studies (Coudeville and Garnett, 2012; Recker et al., 2014; Re-
ich et al., 2013) argue that including the period of cross-protection and increased
transmissibility from individuals suffering from DHF or DSS in secondary infec-
tions are of particular importance to reproduce the multi-annual patterns observed
in surveillance of dengue cases. The work of Reich et al. (2013) provided strong
evidence for substantial cross-protection for an average duration of 1.88 years af-
ter the primary infection. After this period has elapsed, individuals will enter a
period during which the effect of ADE may appear in a secondary infection. This
effect is inversely correlated with the concentration of non-neutralizing antibodies,
and may become inapparent over time due to the decline of antibody concentra-
tion to sufficiently low levels. Thus, high antibody concentrations are assumed
to be protective, low concentrations are irrelevant in the context of ADE, and
medium concentrations are associated with the ADE phenomenon. We assumed
that following the period of partial protection associated with the risk of ADE,
individuals are fully susceptible to other serotypes. The effect of ADE also appears
as increased viral titres in human blood, which in turn influences the likelihood of
a mosquito becoming infected after a bloodmeal (Carrington and Simmons, 2014).
We assumed higher human-to-mosquito transmissibility of the secondary infection
during the partial protection period, compared to the primary infection.
To investigate the effect of vaccine on the dynamics of dengue infection, we
implemented tetravalent (all-serotypes) vaccination in our model for individuals
with no prior exposure to dengue serotypes. We consider two scenarios in which
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Table 1 Serotype-specific variables are labelled with indices 1 and 2 that correspond to S1
and S2. Index A indicates that infection was acquired from a human with high viral titres, and
is associated with the ADE phenomenon. Indices M and L refer to medium and low antibody
levels in the human blood, respectively. All variables are functions of time.
Model variables Description
SV Susceptible mosquitoes
F 1V = δˆ1
I1H+I
L1
H
H
Force of infection with S1 in mosquito population without ADE effect
F 2V = δˆ2
I2H+I
L2
H
H
Force of infection with S2 in mosquito population without ADE effect
FA1V = δˆ1
σ1I
M1
H
H
Force of infection with S1 in mosquito population with ADE effect
FA2V = δˆ2
σ2I
M2
H
H
Force of infection with S2 in mosquito population with ADE effect
E1V , E
2
V , E
A1
V , E
A2
V Exposed mosquitoes
I1V , I
2
V , I
A1
V , I
A2
V Infectious mosquitoes
SH Susceptible humans
WH Vaccinated humans, fully protected
XH Vaccinated humans, partially protected
Y 1H , Y
2
H Vaccinated humans with exposure to S1, S2 (in the modified model)
Z1H , Z
2
H Vaccinated humans with infection of S1, S2 (in the modified model)
F 1H = λ1
I1V +I
A1
V
H
Force of infection with S1 in human population
F 2H = λ2
I2V +I
A2
V
H
Force of infection with S2 in human population
E1H , E
2
H Humans with primary exposure to S1, S2
I1H , I
2
H Humans with primary infection of S1, S2
T 1H , T
2
H Humans recovered from primary infection with cross-protection
SM1H , S
M2
H Humans partially susceptible to secondary infection
SL1H , S
L2
H Humans fully susceptible to secondary infection
EM1H , E
M2
H Humans with secondary exposure to S1, S2, with ADE effect
EL1H , E
L2
H Humans with secondary exposure to S1, S2, without ADE effect
IM1H , I
M2
H Humans with secondary infection of S1, S2, with ADE effect
IL1H , I
L2
H Humans with secondary infection of S1, S2, without ADE effect
RH Humans immune against both serotypes
vaccination is implemented either for the susceptible population, or for newborns
only. We assumed that the vaccine-induced immunity provides some degree of
protection to each serotype. Since vaccination primes the individual’s immune
response to all serotypes, we assumed that vaccinated individuals are subject to
the ADE effect after the period of full protection has elapsed if infection occurs.
2.2 Dengue dynamics in the vector population
We model dengue dynamics with a system of ordinary differential equations, where
all variables depend on time t. First, we develop the subsystem for the mosquito
population. The total mosquito population is denoted by V . The recruitment
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(birth) in the mosquito population is given by the function bˆ(t). We elaborate
on this birth function and its expression in equation (13) when we revisit the
subsystem for the mosquito population. Assuming that all mosquitoes are born
susceptible, and die at the rate µˆ, the dynamics of dengue in susceptible mosquitoes
are governed by
S˙V = bˆ(t)− (F 1V + F 2V + FA1V + FA2V )SV − µˆSV , (1)
where F 1V + F
2
V + F
A1
V + F
A2
V is the force of infection for the vector population,
describing that a susceptible mosquito can acquire dengue S1 or S2 from infectious
individuals. The term for the force of infection in the mosquito population will be
explicitly defined in Section 2.3.
Since mosquitoes infected by individuals experiencing DHF or DSS (i.e., the ef-
fect of ADE with high viral titres) may become infectious in a significantly shorter
incubation period compared to mosquitoes that acquire dengue from infectious
individuals with mild form of infection (Carrington and Simmons, 2014), we as-
sumed two different extrinsic incubation periods 1/αˆ and 1/αˆA . For the exposed
classes in the mosquito population we obtain the system
E˙1V = F
1
V SV − (αˆ+ µˆ)E1V , E˙A1V = FA1V SV − (αˆA + µˆ)EA1V ,
E˙2V = F
2
V SV − (αˆ+ µˆ)E2V , E˙A2V = FA2V SV − (αˆA + µˆ)EA2V ,
(2)
where index A indicates if infection was acquired from a human with high viral
titres, that is associated with the ADE phenomenon.
After the extrinsic incubation period has elapsed, infectious mosquitoes are
able to transmit the disease and are part of the infection classes that correspond
to their exposed compartments. Assuming that such mosquitoes remain infectious
for the remaining part of their lifespan, the dynamics of infectious mosquitoes can
be expressed by
I˙1V = αˆE
1
V − µˆI1V , I˙A1V = αˆAEA1V − µˆIA1V ,
I˙2V = αˆE
2
V − µˆI2V , I˙A2V = αˆAEA2V − µˆIA2V .
(3)
2.3 Dengue dynamics in the human population
We define the force of infection for S1 and S2 in the human population by
F 1H = λ1
I1V + I
A1
V
H
, F 2H = λ2
I2V + I
A2
V
H
, (4)
where H is the total human population, and λ1 and λ2 are respectively the rates at
which mosquitoes transmit S1 and S2 to humans. Denoting susceptible individuals
by SH , the equation
S˙H = (1− φ)B − (F 1H + F 2H)SH − ξSH − µSH , (5)
describes the dynamics of infection in humans, where B is the constant birth rate
and µ is the natural death rate. Susceptible individuals are vaccinated at a rate ξ
and move to the classWH . The parameter φ represents the vaccination coverage of
newborns. If φ > 0, a fraction φ of newborns are vaccinated and recruited directly
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to the WH class. We assume that vaccinated individuals will be fully protected
for a period of time (1/η). After this period has elapsed, they move to the class of
individuals with partial protection (XH), who are subject to ADE for the rest of
their lifetime. The governing equations are
W˙H = φB + ξSH − ηWH − µWH ,
X˙H = ηWH − (p1F 1H + p2F 2H)XH − µXH ,
(6)
where the parameters 0 ≤ p1 ≤ 1 and 0 ≤ p2 ≤ 1 represent respectively the re-
duced probabilities of acquiring infection with S1 and S2 due to partial protection.
After exposure to a serotype, individuals enter the exposed classes E1H and
E2H , with average latency periods of 1/α1 and 1/α2 units of time, before becoming
infectious. Primary infections with S1 (individuals in I1H) and S2 (individuals in
I2H) will recover at the rates γ1 and γ2, respectively, and move to the corresponding
classes T 1H and T
2
H with full protection. The equations describing such dynamics
are
E˙1H = F
1
H SH − α1E1H − µE1H ,
I˙1H = α1E
1
H − µI1H − γ1I1H ,
T˙ 1H = γ1I
1
H − ρ1T 1H − µT 1H ,
(7)
and
E˙2H = F
2
H SH − α2E2H − µE2H ,
I˙2H = α2E
2
H − µI2H − γ2I2H ,
T˙ 2H = γ2I
2
H − ρ2T 2H − µT 2H ,
(8)
where ρ1 and ρ2 are respectively the rates at which individuals in the T 1H and T
2
H
classes lose their full protection. We assume that recovery after the primary infec-
tion with a particular serotype provides lifelong immunity against that serotype.
After the transient period of full protection has elapsed, individuals move to the
class SM2H (or S
M1
H ) and become susceptible to infection with S2 (or S1). While
this susceptibility is reduced by a factor q2 (or q1) due to partial protection, the
secondary infection (if occurs) is subject to ADE. As the partial protection wanes
over time, individuals become fully susceptible and the secondary infection may
occur without the ADE effect. The infection dynamics are described by the fol-
lowing equations:
S˙M2H = ρ1T
1
H − q2 F 2H SM2H − (µ+ θ2)SM2H ,
S˙L2H = θ2S
M2
H − F 2H SL2H − µSL2H ,
S˙M1H = ρ2T
2
H − q1 F 1H SM1H − (µ+ θ1)SM1H ,
S˙L1H = θ1S
M1
H − F 1H SL1H − µSL1H .
(9)
where θ2 and θ1 are the rates at which individuals move from the SM2H and S
M1
H
classes to SL2H and S
L1
H , and become fully susceptible to heterologous infections.
Individuals exposed to S1 and S2 as secondary infection move to the classes
EM1H and E
M2
H with the ADE effect, or to the classes E
L1
H and E
L2
H without
the ADE effect. After the exposed period has elapsed, disease progression with
the secondary infection in IM1H , I
L1
H , I
M2
H , and I
L2
H is identical to that with the
primary infection, and recovery from secondary infection will confer full protection
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Table 2 Serotype-specific parameters are labelled with indices 1 and 2 that correspond to S1
and S2. Index A indicates that infection was acquired from a human with high viral titres,
and is associated with the ADE phenomenon.
Parameters Description
µˆ Death rate of the mosquito population
δˆ1, δˆ2 Transmission rates of S1 and S2 from human to mosquito
1/αˆA , 1/αˆ Average extrinsic incubation periods
B Birth rate of the human population
µ Natural death rate of the human population
φ Vaccination coverage of newborns
ξ Vaccination rate of susceptible individuals
λ1, λ2 Transmission rates of S1 and S2 from mosquito to human
1/α1, 1/α2 Average intrinsic incubation periods
γ1, γ2 Recovery rates of S1 and S2 in the human population
1/ρ1, 1/ρ2 Average duration of cross-protection after primary infection
1/θ1, 1/θ2 Average duration of partial protection after primary infection
q1, q2 Reduced susceptibility to secondary infection during partial protection
p1, p2 Reduced susceptibility to infection after vaccination during
partial protection
σ1, σ2 Enhanced transmissibility of human (with ADE effect) to mosquito
κ1, κ2 Enhanced transmissibility of human (with ADE effect) to mosquito
after vaccination (in the modified model only)
1/η Average duration of full protection following vaccination
against both serotypes. Since vaccinated individuals have already been primed to
all serotypes, infection during partial protection will be considered as secondary
infection with the ADE effect. In our model, this means that new infections with
S1 and S2 from the class XH move to EM1H and EM2H , respectively. The following
equations express such dynamics mathematically as
E˙M2H = q2 F
2
H S
M2
H + p2 F
2
H XH − α2EM2H − µEM2H ,
I˙M2H = α2E
M2
H − µIM2H − γ2IM2H ,
E˙M1H = q1 F
1
H S
M1
H + p1 F
1
H XH − α1EM1H − µEM1H ,
I˙M1H = α1E
M1
H − µIM1H − γ1IM1H ,
(10)
E˙L2H = F
2
H S
L2
H − α2EL2H − µEL2H ,
I˙L2H = α2E
L2
H − µIL2H − γ2IL2H ,
E˙L1H = F
1
H S
L1
H − α1EL1H − µEL1H ,
I˙L1H = α1E
L1
H − µIL1H − γ1IL1H ,
(11)
and
R˙H = γ1(I
L1
H + I
M1
H ) + γ2(I
L2
H + I
M2
H )− µRH , (12)
where RH is the class of individuals immune against both serotypes.
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Now, we revisit our subsystem for dengue dynamics in the mosquito population.
Recruitment into the mosquito population is modelled by the non-autonomous
(seasonal-dependent) birth term (Wearing and Rohani, 2006)
bˆ(t) = kHµˆ(1− a cos(2pit)), (13)
where k is the average number of mosquitoes per person, and a is the amplitude
of seasonal fluctuation. In the absence of seasonality, recruitment to the vector
population is proportional to the total human population. We define the force of
infection functions F 1V , F
A1
V , F
2
V , and F
A2
V in the mosquito subsystem as
F 1V = δˆ1
I1H + I
L1
H
H
, FA1V = δˆ1
σ1I
M1
H
H
,
F 2V = δˆ2
I2H + I
L2
H
H
, FA2V = δˆ2
σ2I
M2
H
H
,
(14)
where δˆ1 and δˆ2 are the transmission rates of S1 and S2, respectively, from humans
to mosquitoes, and σ1 and σ2 represent the enhanced transmissibility due to the
ADE effect. Summarizing the above, the joint systems (1)–(3) and (5)–(12) with
the functions (4) and (14) give a system of differential equations for the dynamics
of dengue in the mosquito and human populations. Variables and parameters of
the model are listed in Tables 1 and 2.
Standard arguments from the theory of ordinary differential equations guaran-
tee that the system for dengue dynamics in the mosquito and human populations
admits a unique solution. For the total human population H, there is a globally
attracting equilibrium H¯ = B/µ, that is, limt→∞H(t) = B/µ. The dynamics of
the total mosquito population is given by
V˙ = bˆ(t)− µˆV.
Considering H = H¯ and the constant recruitment term bˆ(t) = kH¯µˆ (without
seasonal variation) in the vector population, the equation bˆ(t) − µˆV = 0 has a
unique solution V¯ = kH¯, and the total mosquito population converges, that is,
limt→∞ V (t) = V¯ .
Non-negative initial conditions give rise to non-negative solutions of the system,
and therefore the solutions are bounded, and thus exist for all times. When the
human population is at the disease-free state (i.e., F 1V +F
2
V +F
A1
V +F
A2
V = 0), the
subsystem for mosquito dynamics admits a unique equilibrium, at which SV (t) ≡
V¯ and all other classes are at zero states (i.e., the disease-free equilibrium). When
there is no infection in the human population, the unique steady state is globally
stable. Similarly, when the mosquito population is at the disease-free state (i.e.,
F 1H + F
2
H = 0), the subsystem for human population admits a unique equilibrium
with
SH(t) ≡ (1− φ)B
ξ + µ
, WH(t) ≡ φB
η + µ
+
ξ(1− φ)B
(ξ + µ)(η + µ)
,
XH(t) ≡ ηφB
(η + µ)µ
+
ηξ(1− φ)B
(ξ + µ)(η + µ)µ
,
and all other classes are at zero states, which is the disease-free equilibrium. With
no infection in the mosquito population, the unique steady state is globally stable.
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2.4 The modified model
We modify the original model to incorporate the possible difference in the en-
hanced transmissibility of human to mosquito due to the ADE effect in vaccinated
individuals. We include the classes Y 1H and Y
2
H for vaccinated individuals exposed
to S1 and S2, respectively, and introduce Z1H and Z2H for the corresponding in-
fection classes. The parameter κ1 and κ2 represent the enhanced transmissibility
factors. With these modifications, the system (10) for the dynamics of the human
population is expressed by
E˙M2H = q2 F
2
H S
M2
H − α2EM2H − µEM2H ,
I˙M2H = α2E
M2
H − µIM2H − γ2IM2H ,
E˙M1H = q1 F
1
H S
M1
H − α1EM1H − µEM1H ,
I˙M1H = α1E
M1
H − µIM1H − γ1IM1H ,
Y˙ 2H = p2 F
2
H XH − α2Y 2H − µY 2H ,
Z˙2H = α2Y
2
H − µZ2H − γ2Z2H ,
Y˙ 1H = p1 F
1
H XH − α1Y 1H − µY 1H ,
Z˙1H = α1Y
1
H − µZ1H − γ1Z1H ,
and we revise the equation (12) to
R˙H = γ1(I
L1
H + I
M1
H + Z
1
H) + γ2(I
L2
H + I
M2
H + Z
2
H)− µRH ,
for the class of individuals recovered from both serotypes. The force of infection
terms in equation (14) for serotypes acquired from infectious humans with the
ADE effect are also redefined as
FA1V = δˆ1
σ1I
M1
H + κ1 Z
1
H
H
, FA2V = δˆ2
σ2I
M2
H + κ2 Z
2
H
H
.
3 Serotype-specific reproduction numbers
In this section, we consider the birth term in the mosquito population without
seasonal variation, which guarantees that the full system for dengue dynamics has
a unique disease-free equilibrium. We define the reproduction number of serotype
Si (i = 1, 2) in the absence of vaccination. This number, denoted here by Ri,
gives the average number of new infections generated by a single infectious case
in a wholly susceptible population. To provide an expression for this quantity, we
apply the next-generation method, initially formalized by (Diekmann et al., 1990).
In this method, the reproduction number arises as the dominant eigenvalue of the
next-generation matrix at the disease-free state (Diekmann et al., 1990, 2010).
In the absence of vaccination, the disease-free equilibrium involves only two
non-zero components, H¯ and V¯ for the susceptible human and mosquito classes,
respectively. Following the procedure described in (Diekmann et al., 2010) for
obtaining Ri, we identify the infection subsystem as the equations in the com-
partmental model that describe the generation of new infections and changes in
the epidemiological status among infected individuals and mosquitoes. In the case
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when only one serotype is present, secondary infection in humans is impossible
and the infection subsystem for humans consists of only EiH and I
i
H . Without
secondary infections, the compartments EAiV , I
Ai
V are zero, and we only need to
consider the classes EiV , I
i
V for the dynamics of infected mosquitoes. The infection
subsystem is given by the four equations describing EiV and I
i
V , E
i
H , and I
i
H .
During the initial phase of an epidemic, the changes in the susceptible populations
are negligible; thus one can approximate the dynamics in these four classes by
linearizing the infection subsystem about the disease-free state. The matrix of the
linearized system is decomposed as Ti +Σi, where Ti describes the production of
new infections (transmission parts in the linear approximation), and Σi represents
changes in the status, as become infected, recover from infection, or die (transition
parts in the linear approximation). These matrices are
Ti =

0 0 0 δˆi
V¯
H¯
0 0 0 0
0 λi 0 0
0 0 0 0
 , Σi =

−(αˆ+ µˆ) 0 0 0
αˆ −µˆ 0 0
0 0 −(αi + µ) 0
0 0 αi −(γi + µ)
 .
The product of Ti and −Σ−1i gives:
−TiΣ−1i =

0 0
δˆiαiV¯
(αi + µ)(γi + µ)H¯
δˆiV¯
(γi + µ)H¯
0 0 0 0
αˆλi
(αˆ+ µˆ)µˆ
λi
µˆ
0 0
0 0 0 0
 .
Following the description provided in (Diekmann et al., 2010) to derive the next-
generation matrix Ki from −TiΣ−1i , we obtain
Ki =
 0
δˆiαiV¯
(αi + µ)(γi + µ)H¯
αˆλi
(αˆ+ µˆ)µˆ
0
 , (15)
where [Ki]12 is the average number of mosquitoes infected by a single infectious hu-
man, and [Ki]21 is the average number of humans that a single infectious mosquito
infects, in a wholly susceptible population. Eigenvalues of Ki are the solutions of
x2 −
(
αˆλi
(αˆ+ µˆ)µˆ
)(
δˆiαiV¯
(αi + µ)(γi + µ)H¯
)
= 0.
The dominant eigenvalue of the next-generation matrix is therefore obtained as
ρ(Ki) =
√√√√( αˆλi
(αˆ+ µˆ)µˆ
)(
δˆiαiV¯
(αi + µ)(γi + µ)H¯
)
,
and the disease-free state is locally asymptotically stable (unstable) in the model
with only one serotype if ρ(Ki) < 1 (ρ(Ki) > 1) (Diekmann et al., 2010).
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A different approach to calculating the reproduction number for one serotype
can also be taken by tracing an infectious mosquito and an infectious human during
their exposed and infectious periods. This method yields [Ki]21 and [Ki]12 respec-
tively. As humans cannot infect humans, two generations are required to transmit
an infection from human to human, the first being from human to mosquito and
the second being from mosquito to human. Therefore, the two-generation factor
arises as [Ki]21 · [Ki]12, and the average number of secondary infected mosquitoes
that result from a single infectious mosquito is obtained by the same calculations.
The average next-generation factor Ri is therefore the square root of the two-
generation factor, given by
Ri =
√√√√( αˆλi
(αˆ+ µˆ)µˆ
)(
δˆiαiV¯
(αi + µ)(γi + µ)H¯
)
. (16)
In the absence of a different serotype and vaccination, the circulating serotype
invades the population of humans if Ri > 1 and dies out if Ri < 1.
4 Parameterization
Dengue vectors have a life cycle that is influenced by seasonal variation and sev-
eral climatic factors. To parameterize the model for simulations, we return to the
formula (13) and incorporate seasonality into the recruitment of adult mosquitoes.
We consider the initial total human population at the steady state H0 = 5× 105,
and assume that there are two vectors per human (Wearing and Rohani, 2006),
with the initial total mosquito population of V0 = 106. With a = 0.05, bˆ(t) in (13)
becomes
bˆ(t) = 106µˆ(1− 0.05 cos(2pit)).
To calculate the transmission rates δˆi and λi, we use the expression (16). Assuming
that δˆi = λi (Wearing and Rohani, 2006), for a given Ri and fixed parameters,
transmission rates can be calculated from the expression (16) when V¯ and H¯ are
the initial number of mosquito and human populations, respectively.
Epidemiological parameters describing the average extrinsic incubation peri-
ods (1/αˆA , 1/αˆ), the intrinsic incubation periods (1/α1, 1/α2), and the infectious
periods in humans (1/γ1, 1/γ2) were derived from the literature (Carrington and
Simmons, 2014; Coudeville and Garnett, 2012; Lourenco and Recker, 2013; Wear-
ing and Rohani, 2006). Previous work (Carrington and Simmons, 2014) indicates
that high viral titres during DHF or DSS may shorten the extrinsic incubation
period for mosquitoes, and we therefore assumed αˆA > αˆ (See Table 3 for values
and ranges of parameters used in our simulations).
The duration of cross-protection between serotypes after recovery from the
primary infection has been estimated in the range 0.88–4.31 years (95% confidence
interval), with an average of 1.88 years (Reich et al., 2013). We therefore assumed
1/ρ1 = 1/ρ2 = 1.88 years. Following the transient period of cross-protection, pre-
existing immunity wanes to levels that can no longer completely neutralize the
heterotypic serotypes. Since the susceptibility is reduced, a secondary heterologous
infection can occur with a transmission probability that is lower than that for the
primary infection. We assumed a duration of 5 years for reduced susceptibility
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Table 3 Model parameters and their value (range) derived from the published literature
(Capeding et al., 2014; Carrington and Simmons, 2014; Coudeville and Garnett, 2012; Hss
et al., 2013; Lourenco and Recker, 2013; Reich et al., 2013; Villar et al., 2014; Wearing and
Rohani, 2006).
Parameter Baseline value Range
1/µˆ 15 days 8–42 days
1/αˆA 8 days 7–14 days
1/αˆ 12 days 7–14 days
1/µ 70 years assumed
1/α1, 1/α2 4 days 3–8 days
1/γ1, 1/γ2 6 days 4–12 days
1/ρ1, 1/ρ2 1.88 years 1–3 years
1/θ1, 1/θ2 5 years assumed
p1 0.55 0.35–0.71
p2 0.25 0.18–0.38
q1, q2 variable 0–1
σ1, σ2 2 1–3
1/η 1.88 years varied
κ1, κ2 2 1–3
R1 for S1 3.5 2–8
R2 for S2 2.5 2–8
to heterologous serotypes after the period of cross-protection. We simulated the
model for different reduction factors in susceptibility when the level of partial
protection against the secondary infection is high (q1 = q2 = 0.25) or moderate
to low (q1 = q2 = 0.75). Most studies (Coudeville and Garnett, 2012; Lourenco
and Recker, 2013; Reich et al., 2013) consider the strength of ADE (enhanced
transmissibility) in the range 1–3, and we therefore assumed σ1 = σ2 = 2.
Clinical trials of a tetravalent vaccine candidate indicate the range 40–50% of
vaccine efficacy for DENv1 and DENv2, and 74–77% for DENv3 and DENv4 (Vil-
lar et al., 2014). Based on these estimates, we consider reduction factors p1 = 0.55
and p2 = 0.25 for transmission rates following vaccination. Other recent studies
(Capeding et al., 2014; Hss et al., 2013) also estimate similar efficacies for the
tetravalent vaccine candidate, with a more balanced immune response against all
four serotypes after three doses of vaccine in children. Since the effect of vaccine-
induced ADE is unknown, we assumed the baseline enhanced transmissibilities
κ1 = κ2 = 2 that are the same as enhanced transmissibilities for the secondary
infection after the primary infection in unvaccinated individuals. We simulated the
effect of vaccination on the dynamics of dengue outbreaks by considering differ-
ent vaccine coverages for newborns (φ) and vaccination rates for the susceptible
population (ξ).
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Panel A: vaccination of only newborns Panel B: vaccination of susceptible individuals
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Fig. 2 Time profiles of infections caused by S1 (black curves) and S2 (red curves) for different
vaccination coverages of newborns (Panel A) and vaccination rates of susceptible individuals
(Panel B). The left and right columns in each panel correspond to the total number of dengue
cases and the total number of dengue cases experiencing the ADE effect of both serotypes.
Parameter values are αˆ = 365/12, αˆA = 365/8, µ = 1/70, µˆ = 365/15, α1 = 365/4, α2 =
365/4, γ1 = γ2 = 365/6, ρ1 = ρ2 = η = 1/1.88, and θ1 = θ2 = 1/5 per year, with R1 = 3.5,
R2 = 2.5, σ1 = σ2 = 2, κ1 = κ2 = 2, q1 = q2 = 0.25, p1 = 0.55, and p2 = 0.25.
5 Simulations
We simulated the model to explore the dynamics of dengue outbreaks in the pres-
ence of two serotypes (S1 and S2) with different transmissibilities, reflected in the
corresponding reproduction numbers R1 = 3.5 and R2 = 2.5. These values are
within the ranges reported in previous work (Ferguson et al, 1999b; Wearing and
Rohani, 2006). To evaluate the effect of vaccination, we ran simulations for an
extended period of time to bypass the transient behaviour of the system.
Using current estimates for vaccine efficacy, Figure 2 shows that increasing
vaccination coverage or vaccination rate reduces the overall burden (i.e., the total
number of infections) of both serotypes S1 and S2. We observed that vaccina-
tion interferes with the oscillatory patterns of dengue outbreaks of both serotypes,
causing damped oscillations that approach a steady state in shorter time period
following vaccination as the vaccine coverage or rate increases. Furthermore, the
number of dengue cases with S2 who are subject to ADE decreases and stabi-
lizes over several years (Figure 2; right columns in panels A and B, red curves).
However, while the number of dengue cases with S1 who are subject to ADE will
stabilize over the years (through damped oscillations) for a low vaccine coverage
or rate (φ = 0.1, ξ = 0.1), it rises with increase in the vaccination coverage or
rate to numbers potentially greater than what is observed in simulations without
vaccination (Figure 2; right columns in panels A and B, black curves). A possi-
ble explanation is the difference in transmissibilities of S1 and S2 at the time for
start of vaccination, and the efficacy of vaccine which is higher for serotype S2
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Fig. 3 Time profiles of infections caused by S1 (black curves) and S2 (red curves) for different
vaccination coverages of newborns (Panel A) and vaccination rates of susceptible individuals
(Panel B). The left and right columns in each panel correspond to the total number of dengue
cases and the total number of dengue cases experiencing the ADE effect of both serotypes.
Parameter values are αˆ = 365/12, αˆA = 365/8, µ = 1/70, µˆ = 365/15, α1 = 365/4, α2 =
365/4, γ1 = γ2 = 365/6, ρ1 = ρ2 = η = 1/1.88, and θ1 = θ2 = 1/5 per year, with R1 = 3.5,
R2 = 2.5, σ1 = σ2 = 2, κ1 = κ2 = 2, q1 = q2 = 0.25, and p1 = p2 = 0.05.
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Fig. 4 Time profiles of infections caused by S1 (black curves) and S2 (red curves) for different
vaccination coverages of newborns (Panel A) and vaccination rates of susceptible individuals
(Panel B). The left and right columns in each panel correspond to the total number of dengue
cases and the total number of dengue cases experiencing the ADE effect of both serotypes.
Parameter values are αˆ = 365/12, αˆA = 365/8, µ = 1/70, µˆ = 365/15, α1 = 365/4, α2 =
365/4, γ1 = γ2 = 365/6, ρ1 = ρ2 = η = 1/70, and θ1 = θ2 = 1/5 per year, with R1 = 3.5,
R2 = 2.5, σ1 = σ2 = 2, κ1 = κ2 = 2, q1 = q2 = 0.25, and p1 = p2 = 0.
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than for S1. We obtained qualitatively similar results when comparing scenarios
of q1 = q2 = 0.25 versus q1 = q2 = 0.75, and κ1 = κ2 = 1 versus κ1 = κ2 = 2.
However, regardless of the level of partial protection, we observed an interesting
phenomenon that for high values of the vaccination coverage or rate, the sce-
nario without enhanced transmissibility (κ1 = κ2 = 1) leads to higher numbers of
dengue infections with both serotypes S1 and S2 compared to the scenario with
enhanced transmissibility (κ1 = κ2 = 2) following vaccination. Summarizing these
results, we note that with current estimates of the serotype-specific vaccine effica-
cies, containing dengue outbreaks is infeasible, even when the vaccination coverage
of newborns is nearly 100%. This conclusion holds true even for a high efficacy vac-
cine if the period of vaccine-induced protection is shorter than the average lifetime
of the human population. Figure 3 illustrates these results where we considered
1.88 years for the period of full protection following vaccination, and 95% protec-
tion afterwards. We obtained similar results for longer period of full protection
(10–50 years; illustration not included here).
We simulated the model for a hypothetical scenario in which the vaccine pro-
vides lifetime protection to both serotypes (Figure 4). With baseline values of
other parameters given in Table 2, we observed that oscillatory patterns of dengue
outbreaks are preserved for a low to moderate vaccine coverage (φ = 0.1, 0.4). For
a high vaccine coverage (φ = 0.8), inter-outbreak periods are extended compared
to a low to moderate vaccine coverage of newborns. For a sufficiently high vac-
cine coverage (φ = 0.95), both serotypes disappear from the population within
10 years following the start of vaccination. In contrast to previous scenarios, we
do not observe any increase in the number of dengue cases of either serotypes
subject to ADE with increase in the vaccine coverage. Compared with the results
presented in Figure 3 (panel A) with a high vaccine efficacy (95% against both
serotypes), our simulations suggest that containing dengue outbreaks may be fea-
sible with a high vaccination coverage of newborns only if the vaccine provides
lifetime protection against all serotypes (Figure 4, panel A). The time profiles of
infections for the scenarios with vaccination of the susceptible individuals (ξ > 0)
are similar to those in the scenarios with vaccination of the newborns. As evident
from these simulations, the time profiles of dengue serotypes stabilize in a shorter
time period with reduced oscillatory behaviour for the scenarios with vaccination
of the susceptible population compared to the scenarios with vaccination of only
newborns.
6 Discussion
In this paper, we developed and analyzed a full model of vector-host interactions for
dengue spread with two serotypes of the virus co-circulating in the mosquito and
human populations. Our model incorporates the phenomena of cross-protection
(which decreases the risk of heterologous infection) and cross-enhancement (which
increases the transmissibility of the virus from human to mosquito). In addition
to cross-protection and cross-enhancement, we incorporated seasonality that has
been reported to be a key factor in dengue dynamics.
By means of simulations, we have shown several important scenarios for the
impact of vaccination on dengue prevention. First and foremost is the fact that
dengue eradication is not feasible with the current estimates of vaccine efficacy
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against different serotypes (Capeding et al., 2014; Villar et al., 2014). Conspic-
uously, higher vaccine coverages or newborns or vaccination rates of susceptible
individuals lead to a lower total number of dengue infections. However, the total
number of dengue cases experiencing the ADE effects may increase over time if the
vaccine-induced protection is imperfect or the duration of its protection is shorter
than the lifetime of the host population. In contrast to previous work that sug-
gests a transient period of higher prevalence following vaccination compared to the
pre-vaccination era when the vaccine efficacy is very low or very high (Pandey and
Medlock, 2014), our model shows a considerable reduction in the overall disease
burden, regardless of the vaccine efficacy. Paradoxically, we observed even lower
incidence of dengue cases subject to ADE immediately after the introduction of
vaccine, and later increase in number of such infections (Figures 2 and 3; right
columns in each panel). These observations remain intact with variation in other
parameters associated with cross-enhancement and naturally-acquired immunity.
Our model is subject to a number of limitations that warrant further investiga-
tion. We considered only two serotypes of dengue; however, the inclusion of all four
serotypes will provide more realistic scenarios for dengue dynamics. Since studies
of the vaccine efficacy involve healthy children (Capeding et al., 2014; Villar et
al., 2014), the potential benefits of immunization to different age groups due to
indirect effects of herd immunity remain unaddressed. In the absence of vaccina-
tion and other pharmaceutical measures, public health interventions are mainly
devised and deployed around vector control programs. In order to determine the
impact of vaccination, we did not included the effect of vector control programs
in our model. These programs have shown to significantly reduce the dengue in-
cidence in several population settings, especially when combined with improved
outbreak prediction and detection through coordinated epidemiological and ento-
mological surveillance (WHO, 2012). Our model could be expanded to incorporate
these measures to reveal potential effects of combined vaccination and vector con-
trol programs on the long-term dynamics of dengue infection. Although we have
relied on parameter values reported in the previous literature, we acknowledge the
possible uncertainty in their estimates. Despite these limitations, the findings of
this study have important implications for vaccination strategies, suggesting that
other vector control measures may still play a key role in dengue prevention when
vaccine becomes available.
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